The overall objective of the Clinical Core is to provide human specimens for the studies described in Research Projects 1-3. These specimens will supplement the existing extensive collection of unique banked specimens that are being used and accrued in the current CCHI. Note: the core will only obtain human specimens from subjects who are receiving the standard-of-care (e.g., vaccinated with the Ty21a typhoid vaccine because of travel to endemic areas or work in microbiology labs, or undergoing medically-indicated colonoscopies) and do not involve off-label interventions. The goals of this core will be achieved through the following specific aims.

Public Health Relevance

The availability of human specimens will be a crucial resource for the three Research Projects (RPI-3) and their goals to comprehensively study the local and systemic immune response to vaccination, evaluate the role of the gut microbiome, and measure the role of the micro-milieu in response to S. Typhi. The Clinical Core will support the interrelated, complementary, interactive goals of RPI-3.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082655-06
Application #
8726153
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Haney, Douglas J; Lock, Michael D; Gurwith, Marc et al. (2018) Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection. Vaccine 36:2768-2773
Davis, Courtney L; Wahid, Rezwanul; Toapanta, Franklin R et al. (2018) A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. PLoS One 13:e0189571
Toapanta, Franklin R; Bernal, Paula J; Kotloff, Karen L et al. (2018) T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. J Transl Med 16:61
Zhang, Yan; Brady, Arthur; Jones, Cheron et al. (2018) Compositional and Functional Differences in the Human Gut Microbiome Correlate with Clinical Outcome following Infection with Wild-Type Salmonella enterica Serovar Typhi. MBio 9:
Senger, Stefania; Ingano, Laura; Freire, Rachel et al. (2018) Human Fetal-Derived Enterospheres Provide Insights on Intestinal Development and a Novel Model to Study Necrotizing Enterocolitis (NEC). Cell Mol Gastroenterol Hepatol 5:549-568
Sztein, Marcelo B (2018) Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? CD8 T-Cell-Mediated Protective Immunity and Vaccination against Enteric Bacteria. Cold Spring Harb Perspect Biol 10:
Salerno-Gonçalves, Rosângela; Tettelin, Hervé; Lou, David et al. (2017) Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells. PLoS Negl Trop Dis 11:e0005912
Booth, Jayaum S; Patil, Seema A; Ghazi, Leyla et al. (2017) Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans. Cell Mol Gastroenterol Hepatol 4:419-437
Fresnay, Stephanie; McArthur, Monica A; Magder, Laurence S et al. (2017) Importance ofSalmonellaTyphi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. Front Immunol 8:208
Salerno-Goncalves, Rosângela; Luo, David; Fresnay, Stephanie et al. (2017) Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. Front Immunol 8:398

Showing the most recent 10 out of 59 publications